This conference examines key issues for the use and uptake of biosimilars in the NHS.

The conference takes place with the UK’s final regulatory guidance for biosimilars expected shortly, following the end of the transition from the EU, as well as the drive within the NHS to reduce medicine costs and achieve value for money.

Areas for discussion include:

• opportunities and next steps for biosimilar development as the UK establishes its own regulatory framework following exit from the EU
• priorities for competition, pricing and access
• progress in achieving value for money and reducing costs through the use of biosimilars
• the role of commissioning and the use of incentives in uptake and cost-effectiveness, as well as tackling variation, improving clinician confidence in prescribing, and patient awareness

The conference is bringing together stakeholders with key policy officials who are due to attend from DHSC; the MHRA; the DIT; the Government Legal Department; and the Scottish Government.